Independent Conference Highlights of the 2022 ASH Annual Meeting*

Download All
December 10-13, 2022; New Orleans, Louisiana
Review slidesets and expert analyses of key studies from the 2022 Hematology Annual Meeting.
Catherine M. Broome, MD
John M. Burke, MD
Corey Cutler, MD, MPH, FRCPC
person default
David Dingli, MD, PhD
Amir T. Fathi, MD
Shaji K. Kumar, MD
Sagar Lonial, MD
Peter Martin, MD
Marshall Mazepa, MD
Srdan Verstovsek, MD, PhD
Eunice S. Wang, MD
Allison Wheeler, MD, MSCI
Amer Zeidan, MBBS, MPH

An Expert’s Guide to ASH 2022: A Preview of the Top Abstracts

Read expert highlights of key studies being presented at the upcoming 2022 ASH Annual Meeting and Exposition. CCO’s Independent Conference Coverage will include all the information you need to understand and integrate the latest oncology data into your clinical practice.

Catherine M. Broome, MD John M. Burke, MD Corey Cutler, MD, MPH, FRCPC person default David Dingli, MD, PhD Amir T. Fathi, MD Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Marshall Mazepa, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Allison Wheeler, MD, MSCI Amer Zeidan, MBBS, MPH Released: December 7, 2022

Acute and Chronic Leukemias

Slidesets V-FAST Subgroup Analysis: CPX-351 + Midostaurin in Newly Diagnosed AML by FLT3 Mutation
Slidesets GRAALL-2014/B Quest Cohort Analysis: Blinatumomab During Consolidation in Adults With High-Risk Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
Slidesets GMALL-INITIAL1: Inotuzumab Ozogamicin Induction Therapy Followed by Standard Chemotherapy in Older Patients With B-Lymphoblastic Leukemia
Slidesets VIALE-A: Extended Follow-up of Azacitidine ± Venetoclax in Patients With Treatment-Naive AML Ineligible for Standard Induction Chemotherapy
Slidesets Phase I/II Trial of Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML
Slidesets Low-Dose Dasatinib for Newly Diagnosed CML: Long-term Follow-up Outcomes
Slidesets AUGMENT-101: Phase I Study of Revumenib in Patients With KMT2A-Rearranged or NPM1-Mutant AML
Slidesets Phase I/II KOMET-001: First-in-Human Study of Ziftomenib, a Novel KMT2A-Menin Inhibitor, in Relapsed/Refractory AML
Slidesets ASC4MORE: Phase II Trial of Addition of Asciminib to Imatinib vs Continued Imatinib vs Switch to Nilotinib in Patients With Chronic-Phase CML Not Achieving Deep Molecular Responses With ≥1 Yr of Imatinib Therapy
Slidesets Phase I/II Trial of Triplet Combination of Gilteritinib + Azacitidine/Venetoclax in Patients With FLT3-Mutated AML: Updated Results
Slidesets ECOG-ACRIN E1910: Phase III Study of Consolidation Chemotherapy ± Blinatumomab in MRD-Negative BCR::ABL1-Negative B-ALL

Lymphomas

Slidesets TRIANGLE: Phase III Trial of Ibrutinib + CIT With or Without ASCT vs CIT Followed by ASCT in Younger Patients With Previously Untreated MCL
Slidesets Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine as Frontline Combination Therapy for Advanced-Stage cHL
Slidesets Pooled Analysis of PhaseED-Seq MRD-Negativity Assessment as Surrogate Endpoint After Frontline Induction Therapy in Patients With DLBCL
Slidesets Phase II Trial: Updated Results of Frontline Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Untreated High-Risk CLL
Slidesets Phase I/II EPCORE NHL-2 Trial Update: Epcoritamab + Rituximab/Lenalidomide in Follicular Lymphoma
Slidesets Acalabrutinib + Lenalidomide and Rituximab With MRD Monitoring in Previously Untreated Mantle Cell Lymphoma
Slidesets Extended Follow-up Results From a Pilot Study of Brentuximab Vedotin + AVD in Newly Diagnosed, Early-Stage, Unfavorable-Risk cHL Using Baseline MTV and PET2 Evaluation
Slidesets CAPTIVATE: 5-Yr Follow-up of Continued Ibrutinib vs Placebo in Patients With CLL/SLL and Undetectable MRD After First-line Ibrutinib + Venetoclax
Slidesets SYMPHONY-1: Phase Ib Results of Tazemetostat + Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Slidesets MATRix/IELSG43: Phase III Trial of High-Dose Chemotherapy + ASCT vs Nonmyeloablative Chemoimmunotherapy as Consolidation for Primary CNS Lymphoma
Slidesets ALPINE: Final Analysis of Zanubrutinib vs Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Slidesets Phase I Trial of Selinexor With Ruxolitinib in Previously Untreated Myelofibrosis
Slidesets Phase II Study of Parsaclisib Add-on Therapy in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results
Slidesets REFINE Cohort 3: Combination Therapy With Navitoclax, a Novel BCL-2 Family Inhibitor, and Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Slidesets Phase II Expansion Study of Ruxolitinib for the Treatment of Symptomatic CMML
Slidesets Sintra-REV: Final Results of Low-Dose Lenalidomide vs Placebo in Non‒Transfusion Dependent Patients With Low-Risk del(5q) MDS
Slidesets Retrospective Analysis for Validation of 2022 WHO and ICC Classification Systems for Patients With Myelodysplastic Syndromes
Slidesets MOMENTUM: Updated Analysis of Momelotinib vs Danazol in Symptomatic, Anemic Patients With Myelofibrosis Previously Treated With a JAKi
Slidesets Phase II Study of Ropeginterferon Alfa-2b for Patients With Dynamic International Prognostic Scoring System Low/Intermediate-1–Risk, Prefibrotic Primary MF
Slidesets JAK2 V617F Molecular Response to Long-term Ruxolitinib Therapy in Patients With PV and ET
Slidesets STIMULUS-MDS1: Randomized, Placebo-Controlled Phase II Trial of Sabatolimab, a TIM-3 Inhibitor, Plus HMA in Higher-Risk MDS

Multiple Myeloma

Slidesets DSMM XIII: Phase III Trial of Rd Induction + ASCT With MEL140 Followed by R Maintenance vs Continuous Rd in Patients 60-75 Yr of Age With Newly Diagnosed MM
Slidesets Phase II GEM-CESAR: Post Hoc Analyses of Sustained uMRD at 4 Yr After KRd + ASCT for High-Risk MM
Slidesets MonumenTAL-1: Phase I/II Study of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Slidesets Phase II KarMMa-2 Cohort 2a: Idecabtagene Vicleucel in Patients With Multiple Myeloma With Early Relapse After Frontline ASCT
Slidesets Phase I/II Trial of Mezigdomide + Dexamethasone in R/R MM: Preliminary Results From the Dose-Expansion Phase II Cohort
Slidesets IFM 2017-03: Phase III Trial of Daratumumab + Lenalidomide vs Lenalidomide + Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma
Slidesets Myeloma XI: Exploring Optimal Duration of Lenalidomide Maintenance After ASCT From Phase III Trial
Slidesets ASCENT: Phase II Study of Fixed-Duration Therapy With Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone for High-Risk Smoldering MM
Slidesets UK OPTIMUM/MUKnine: Phase II Trial of Intensified Dara-VRd Consolidation After ASCT in Ultra-High‒Risk Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia
Slidesets Real-world Multicenter Retrospective Study of Idecabtagene Vicleucel in Patients With R/R MM After Previous BCMA-Targeted Therapy Exposure

Nonmalignant Hematologic Disorders

Slidesets XTEND-1: Analysis of Pain Scores in Phase III Study of Efanesoctocog Alfa Prophylaxis for Patients With Previously Treated Hemophilia A
Slidesets Phase II Trial of Vemircopan (ALXN2050) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Slidesets ADVANCE IV: Phase III Trial of IV Efgartigimod in Adults With Primary Immune Thrombocytopenia
Slidesets CADENZA: Patient-Reported and Quality-of-Life Outcomes From Phase III Study of Sutimlimab vs Placebo in Patients With Cold Agglutinin Disease
Slidesets ATLAS-PPX: Health-Related Quality of Life With Fitusiran Prophylaxis in Patients With Hemophilia A or B With or Without Inhibitors
Slidesets REACH4: Phase I/II Study of Ruxolitinib in Pediatric Patients With Untreated or Steroid-Refractory Acute Graft-vs-Host Disease
Slidesets APPLY-PNH: Phase III Trial of Iptacopan Monotherapy in Patients With Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia With Anti-C5 Therapy
Slidesets BMT CTN 1703: Phase III Trial of PTCy + TAC + MMF vs TAC + MTX for Prevention of GVHD Following Reduced-Intensity Conditioning AlloSCT
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Amgen
Epizyme
GSK
Incyte Corporation
Jazz Pharmaceuticals
Karyopharm Therapeutics Inc.
Novartis Pharmaceuticals Corporation
Sanofi
Seagen

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings